Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals

European Journal of Pharmacology

Volumn 466, Issue 1-2, 2003, Pages 147-154

  Okamoto, Hiroshi ^a   Iwamoto, Yoko ^a   Maki, Mimi ^a   Sotani, Tomohiro ^a   Yonemori, Fumihiko ^a   Wakitani, Korekiyo ^a  

^a JAPAN TOBACCO INC   (Japan)

Author keywords

Cholesteryl ester transfer protein (CETP) inhibitor; High density lipoprotein (HDL) cholesterol; JTT 705

Indexed keywords

1 (2 ETHYLBUTYL)CYCLOHEXANE CARBOXYLIC ACID N (2 MERCAPTOPHENYL)AMIDE; 2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; [2 [[[1 (2 ETHYLBUTYL)CYCLOHEXYL]CARBONYL]AMINO]PHENYL] 2 METHYLPROPANETHIOATE; APOLIPOPROTEIN E; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; JTP 25203; PROTEIN INHIBITOR; THIOL DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

AGAR GEL ELECTROPHORESIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; IC 50; IN VITRO STUDY; LIPID BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; MARMOSET; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RABBIT; SYRIAN HAMSTER;

ADMINISTRATION, ORAL; ANIMALS; CALLITHRIX; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CRICETINAE; ENZYME INHIBITORS; GLYCOPROTEINS; HUMANS; LIPIDS; LIPOPROTEINS; MACACA FASCICULARIS; MALE; RABBITS; SPECIES SPECIFICITY; SULFHYDRYL COMPOUNDS;

EID: 0037432601     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01548-6     Document Type: Article

References (34)

1. Agellon L.B., Walsh A., Hayek T., Moulin P., Jiang X.C., Shelanski S.A., Breslow J.L., Tall A.R. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J. Biol. Chem. 266:1991;10796-10801.
2. Agerholm-Larsen B., Nordestgaard B.G., Steffensen R., Jensen G., Hansen-Tybjaerg A. Elevated HDL cholesterol is a risk factor for ishemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation. 101:2000;1907-1912.
3. Barter P.J., Rye K.-A. High density lipoproteins and coronary heart disease. Atherosclerosis. 121:1996;1-12.
4. Bisgaier C.L., Minton L.L., Essenburg A.D., White A., Homan R. Use of fluorescent cholesteryl ester microemulsions in cholesteryl ester transfer protein assays. J. Lipid Res. 34:1993;1625-1634.
5. Bruce C., Sharp D.S., Tall A.R. Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. J. Lipid Res. 39:1998;1071-1078.
6. Castelli W.P., Garrison R.J., Wilson P.W.F., Abbot R.D., Kalousdian S., Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels; the Framingham study. J. Am. Med. Assoc. 256:1986;2835-2838.
7. Chiba H., Akita H., Tsuchihashi K., Hui S.P., Takahashi Y., Fuda H., Suzuki H., Shibuya H., Tsuji M., Kobayashi K. Quantitative and compositional changes in high density lipoprotein subclasses in patients with various genotypes of cholesteryl ester transfer protein deficiency. J. Lipid Res. 38:1997;1204-1216.
8. Corti M.-C., Guralnik J.M., Salive M.E., Harris T., Field T.S., Wallace R.B., Berkman L.F., Seeman T.E., Glynn R.J., Hennekens C.H., Havlik R.J. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA. 274:1995;539-544.
9. De Grooth G.J., Kuivenhoven J.A., Stalenhoef A.F.H., de Graaf J., Zwinderman A.H., Posma J.L., van Tol A., Kastelein J.J.P. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 105:2002;2159-2165.
10. Drayna D., Jarnagin A.S., McLean J., Henzel W., Kohr W., Fielding C., Lawn R. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature. 327:1987;632-634.
11. Foger B., Chase M., Amar M.J., Vaisman B.L., Shamburek R.D., Paigen B., Fruchart-Najib J., Paiz J.A., Koch C.A., Hoyt R.F., Brewer H.B. Jr., Santamaria-Fojo S. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J. Biol. Chem. 274:1999;36912-36920.
12. Goto A., Sasai K., Suzuki S., Fukutomi T., Ito S., Matsushita T., Okamoto M., Suzuki T., Itoh M., Okumura-Noji K., Yokoyama S. Cholesteryl ester transfer protein and atherosclerosis in Japanese subjects: a study based on coronary angiography. Atherosclerosis. 159:2001;153-163.
13. Hayek T., Masucci-Magoulas L., Jiang X., Walsh A., Rubin E., Breslow J.L., Tall A.R. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J. Clin. Invest. 96:1995;2071-2074.
14. Himanshu V., Poirier K.J., Lee W.H., Satoh Y. Inhibition of cholesterol ester transfer protein by CGS 25159 and changes in lipoproteins in hamsters. Atherosclerosis. 128:1997;59-66.
15. Hirano K., Yamashita S., Kuga Y., Sakai N., Nozaki S., Kihara S., Arai T., Yanagi K., Takami S., Menju M., Ishigami M., Yoshida Y., Kameda-Takemura K., Hayashi K., Matsuzawa Y. Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler. Thromb. Vasc. Biol. 15:1995;1849-1856.
16. Hirano K., Yamashita S., Nakajima N., Arai T., Maruyama T., Yoshida Y., Ishigami M., Sakai N., Kameda-Takemura K., Matsuzawa Y. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler. Thromb. Vasc. Biol. 17:1997;1053-1059.
17. Hope H.R., Heuvelman D., Duffin K., Smith C., Zablocki J., Schilling R., Hegde S., Lee L., Witherbee B., Baganoff M., Bruce C., Tall A.R., Krul E., Glenn K., Connolly D.T. Inhibition of choelsteryl ester transfer protein by substituted dithiobisnicotinic acid dimethyl ester: involvement of a critical cysteine. J. Lipid Res. 41:2000;1604-1614.
18. Inazu A., Koizumi J., Mabuchi H. Cholesteryl ester transfer protein (CETP) deficiency and increased HDL cholesterol levels (hyperalphalipoproteinemia). Jpn. J. Clin. Pathol. 44:1996;322-326.
19. Kobayashi J., Okamoto H., Otabe M., Bujo H., Saito Y. Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage. Atherosclerosis. 162:2002;131-135.
20. Kuivenhoven J.A., Jukema J.W., Zwinderman A.H., de Knijff P., McPherson R., Bruschke A.V.G., Lie K.I., Kastelein J.J.P. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N. Engl. J. Med. 338:1998;86-93.
21. Lagrost L. Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studies. Biochim. Biophys. Acta. 1215:1994;209-236.
22. Marotti K.R., Castle C.K., Boyle T.P., Lin A.H., Murray R.W., Melchior G.W. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 364:1993;73-75.
23. Nofer J.R., Kehrel B., Fobker M., Levkau B., Assmann G., von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis. 161:2002;1-16.
24. Okamoto H., Yonemori F., Wakitani K., Minowa T., Maeda K., Shinkai H. A choesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 406:2000;203-207.
25. Ordovas J.M., Cupples L.A., Corella D., Otvos J.D., Osgood D., Martinez A., Lahoz C., Coltell O., Wilson P.W., Schaefer E.J. Association of cholesteryl ester transfer protein - TaqIB polymorphism with variation in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler. Thromb. Vasc. Biol. 20:2000;1323-1329.
26. Plump A.S., Masucci-Magoulas L., Bruce C., Bisgaier C.L., Breslow J.L., Tall A.R. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl transfer protein transgene expression. Arterioscler. Thromb. Vasc. Biol. 19:1999;1105-1110.
27. Rittershaus C.W., Miller D.P., Thomas L.J., Picard M.D., Honan C.M., Emmett C.D., Pettey C.L., Adari H., Hammond R.A., Beattie D.T., Callow A.D., Marsh H.C., Ryan U.S. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20:2000;2106-2112.
28. Shinkai H., Maeda K., Yamasaki T., Okamoto H., Uchida I. Bis(2-(acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein. J. Med. Chem. 43:2000;3566-3572.
29. Sugano M., Makino N., Sawada S., Otsuka S., Watanabe M., Okamoto H., Kamada M., Mizushima A. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on development of atherosclerosis in cholesterol-fed rabbits. J. Biol. Chem. 273:1998;5033-5036.
30. Tollefson J.H., Albers J.J. Isolation, characterization, and assay of plasma lipid transfer proteins. Methods Enzymol. 129:1986;797-816.
31. Von Eckardstein A., Nofer J.R., Assmann G. High density lipoproteins and artheriosclerosis: role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 21:2001;13-27.
32. Whitlock M.E., Swanson T.L., Ramakrishnan R., Leonard T., Marcel Y.L., Milne R.W., Tall A.R. Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit: effects on lipoprotein composition and high density lipoprotein cholesteryl ester metabolism. J. Clin. Invest. 84:1989;129-137.
33. Yuhanna I.S., Zhu Y., Cox B.E., Hahner L.D., Osborne-Lawrence S., Lu P., Marcel Y.L., Anderson R.G.W., Mendelsohn M.E., Hobbs H.H., Shaul P.W. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7:2001;853-857.
34. Zhong S., Sharp D.S., Grove J.S., Bruce C., Yano K., Curb J.D., Tall A.R. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 97:1996;2917-2923.